EssilorLuxottica announces the acquisition of Ikerian AG, the Swiss health technology company founded in 2017 and operating under the RetinAI brand, specializing in AI and data management in eyecare. Franco-Italian vision care giant EssilorLuxottica generated consolidated revenue of Euro 26.5 billion in 2024.

依视路陆逊梯卡宣布收购2017年成立的瑞士健康技术公司Ikerian AG，该公司以RetinAI品牌运营，专注于眼科护理领域的人工智能和数据管理。法意视力护理巨头依视路陆逊梯卡2024年综合营收达265亿欧元。

Iconic brands include Ray-Ban, Oakley and Supreme. The Group is also known for innovation ranging from medical instruments and solutions for eye health to smart glasses..

标志性品牌包括雷朋、奥克利和最高。该集团还以其从医疗仪器和眼健康解决方案到智能眼镜的创新而闻名。

Bern-based

伯尔尼的

RetinAI

视网膜AI

develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets. Its FDA cleared and CE-marked flagship platform, RetinAI Discovery, applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases.

开发先进的工具来收集、处理和评估大规模视网膜图像和生物标记数据集。其获得FDA批准和CE认证的旗舰平台RetinAI Discovery，应用人工智能模型来支持疾病诊断和病情进展监测——包括年龄相关性黄斑变性（AMD）、青光眼和糖尿病视网膜病变——从而帮助更准确和及时地做出眼科疾病管理决策。

At the same time, RetinAI partners with pharmaceutical companies and research organizations that leverage proprietary real-world evidence to accelerate clinical studies and drug development..

同时，RetinAI与制药公司和研究机构合作，利用专有的真实世界证据来加速临床研究和药物开发。

The acquisition reinforces

收购进一步巩固了

EssilorLuxottica’s

依视路陆逊梯卡的

med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights that empower healthcare professionals and enhance patient care.

医疗技术之旅，添加了由机器学习和计算机视觉驱动的先进软件。这些解决方案简化了临床、研究和制药工作流程，并提供了可操作的AI驱动洞察，助力医疗专业人员提升患者护理水平。

As part of Essilor Luxottica, the Swiss scale-up will continue operating as Ikerian AG, expanding its AI-driven solutions and accelerating innovation in ophthalmology and beyond - while keeping the team, mission, and partnerships intact. “This acquisition opens an exciting new chapter for our team and technology.

作为依视路陆逊梯卡集团的一部分，这家瑞士新兴公司将继续以Ikerian AG的名义运营，扩展其人工智能驱动的解决方案，并加速眼科及其他领域的创新——同时保持团队、使命和合作伙伴关系不变。“此次收购为我们的团队和技术开启了令人兴奋的新篇章。

From the start, we’ve believed in the power of data and AI to transform patient care. With EssilorLuxottica’s global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact”, said Carlos Ciller, PhD, Chairman and CEO of RetinAI/Ikerian AG..

“从一开始，我们就相信数据和人工智能在改变患者护理方面的力量。通过依视路陆逊梯卡的全球影响力和对创新的深厚承诺，我们现在可以将这一愿景提升到一个全新的规模和积极影响的水平。” RetinAI/Ikerian AG 的董事长兼首席执行官 Carlos Ciller 博士说道。

EssilorLuxottica is a global leader in the design, manufacture and distribution of advanced vision care products, eyewear and med-tech solutions. The Group is home to the most innovative lens technologies, including Varilux, Stellest and Transitions, iconic brands such as Ray-Ban, Oakley and Supreme, the most desired luxury licensed brands and world-class retailers including Sunglass Hut, LensCrafters, Vision Express and Apollo..

依视路陆逊梯卡是设计、制造和分销先进视力保健产品、眼镜和医疗技术解决方案的全球领导者。该集团拥有最具创新性的镜片技术，包括万里路、星趣控和全视线，以及雷朋、奥克利和Supreme等标志性品牌，还有最炙手可热的奢侈授权品牌，以及包括太阳镜小屋、亮视点、视觉表达和阿波罗在内的世界级零售商。

Backed by robust R&D investments, distinctive capabilities and a top-quality asset portfolio, EssilorLuxottica drives innovation across categories, from cutting-edge medical instruments and solutions for eye health to category-defining smart glasses, all of which push the boundaries of the industry and reimagine the eyes as a gateway to new possibilities.

依托强大的研发投资、独特的能力和高品质的资产组合，EssilorLuxottica推动了各领域的创新，从尖端的眼科仪器和眼健康解决方案到定义类别的智能眼镜，所有这些都突破了行业界限，重新将眼睛定义为通往新可能的门户。

With over 200,000 employees across 150 countries, 600 operations facilities, serving 300,000 eye care professionals and operating 18,000 stores, the Group generated consolidated revenue of Euro 26.5 billion in 2024..

集团在150个国家拥有超过20万名员工，600个运营设施，为30万名眼科护理专业人士提供服务，并经营着18,000家门店，2024年实现综合收入265亿欧元。

“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey. RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence.

“仅在过去一年，我们就已经在医疗技术领域做出了几项大胆的举措，所有这些举措的目标都是构建最全面、数字化赋能的患者旅程。RetinAI 将为一个已经涵盖全面眼科护理、先进诊断、治疗创新和手术卓越的生态系统增添巨大的价值。”

Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more effective disease monitoring. We are ushering in a new era of healthcare, and it will be transformative for patients everywhere', commented Francesco Milleri, Chairman and CEO at EssilorLuxottica..

“通过其人工智能驱动的分析，我们可以将临床数据转化为洞察力，从而实现更快、更准确的诊断和更有效的疾病监测。我们正在迎来一个医疗保健的新时代，这将为世界各地的患者带来变革。”EssilorLuxottica董事长兼首席执行官Francesco Milleri评论道。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送